Multipotent bone marrow-derived stem cells: Phase II started

AlloCure began the double-blind, placebo-controlled, U.S. Phase II ACT-AKI trial to evaluate a single dose of AC607 in 200 cardiac surgery patients who experienced kidney injury within 24 hours of sur...